SIC
KRYS icon

Salem Investment Counselors’s Krystal Biotech KRYS Stock Holding History

Salem Investment Counselors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86K Buy
+5
New +$1.49K ﹤0.01% 1108
2025
Q4 		– Sell
-8
Closed -$1.41K – 811
2025
Q3 		$1.41K Buy
+8
New +$1.2K ﹤0.01% 1101

Other funds holding KRYS

Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PIP
Palisades Investment Partners Santa Monica, California $352M AUM 76.79% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Salem Investment Counselors's KRYS Position: Q2 2026 in Review

Salem Investment Counselors opened a new position in Krystal Biotech (KRYS) in Q2 2026: 5 shares worth $1.86K. The stake represents ﹤0.01% of the portfolio and ranks #1108 among its holdings. This is a return to the name: Salem Investment Counselors previously reported a position in KRYS as recently as Q3 2025.

Salem Investment Counselors first reported a position in KRYS in Q3 2025 and has held it in 2 quarters since. 153 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Salem Investment Counselors held 5 shares of Krystal Biotech worth $1.86K as of Q2 2026.
  • Krystal Biotech was a new Salem Investment Counselors position in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of Salem Investment Counselors's portfolio in Q2 2026, its #1108 holding.
  • Salem Investment Counselors first reported a position in Krystal Biotech in Q3 2025 and has held it in 2 quarters since.
  • 153 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.